Clinical Trial Update: A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial from AbbVie evaluating intravenous Etentamig (ABBV-383) in adults with AL amyloidosis; the study is currently recruiting to assess di…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunoglobulin Light Chain Amyloidosis

Drugs mentioned

• Etentamig

Snippet

Sponsor: AbbVie | Conditions: Immunoglobulin Light Chain (AL) Amyloidosis | Phase 1, Phase 2 | Status: RECRUITING